BACKGROUND: S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (DKK-1), marker of bone remodelling, is also implicated in the process of syndesmophyte formation in ankylosing spondylitis. The aim of our study was to evaluate plasma levels of S100A4 in patients with axial spondyloarthritis and to determine the potential association of S100A4 with disease severity, clinical manifestations and with bone changes in a cross-sectional study. METHODS: Fifty-eight patients with axial spondyloarthritis and 40 healthy controls were studied. Biological samples were analysed for S100A4 and Dickkopf-1. Disease activity was assessed according to the Bath Ankylosing Spondylitis Disease Activity Index. C-reactive protein (CRP) was used as a marker of inflammation. Radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). RESULTS: The plasma levels of S100A4 were significantly higher in patients with axial spondyloarthritis compared to heathy controls (p < 0.0001). The levels of S100A4 were higher in early stages of the disease and lower in patients with the presence of syndesmophytes (p = 0.009). Furthermore, we found weak but significant inverse correlation of plasma S100A4 with the mSASSS (r = - 0.363, p = 0.030). Levels of S100A4 were negatively associated with disease duration (r = - 0.404, p = 0.002) and positively with Dickkopf-1 binding capacity (r = 0.312, p = 0.023). CONCLUSIONS: This is the first study showing elevated circulating levels of S100A4 in patients with axial spondyloarthritis, particularly in early stages of the disease prior to spinal involvement, and its significantly lower levels in patients with syndesmophytes. The role of S100A4 in the pathogenesis of axial spondyloarthritis can be suggested.

Department of Neuroscience and Pharmacology Faculty of Health Sciences University of Copenhagen Copenhagen Denmark

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Zobrazit více v PubMed

Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial Spondyloarthritis. N Engl J Med. 2016;374:2563–2574. doi: 10.1056/NEJMra1406182. PubMed DOI

Ranganathan V, Gracey E, Brown MA, et al. Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nat Rev Rheumatol. 2017;13:359–367. doi: 10.1038/nrrheum.2017.56. PubMed DOI

Arends S, Spoorenberg A, Efde M, et al. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in Ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS One. 2014;9:e99685. doi: 10.1371/journal.pone.0099685. PubMed DOI PMC

Dahlmann M, Okhrimenko A, Marcinkowski P, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget. 2014;5:3220–3233. doi: 10.18632/oncotarget.1908. PubMed DOI PMC

Tomcik Michal, Palumbo-Zerr Katrin, Zerr Pawel, Avouac Jerome, Dees Clara, Sumova Barbora, Distler Alfiya, Beyer Christian, Cerezo Lucie Andres, Becvar Radim, Distler Oliver, Grigorian Mariam, Schett Georg, Senolt Ladislav, Distler Jörg H W. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases. 2014;74(9):1748–1755. doi: 10.1136/annrheumdis-2013-204516. PubMed DOI

Pleštilová L, Mann H, Andrés Cerezo L, et al. The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. Arthritis Res Ther. 2014;16:468. doi: 10.1186/s13075-014-0468-2. PubMed DOI PMC

Klingelhöfer J, Šenolt L, Baslund B, et al. Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2007;56:779–789. doi: 10.1002/art.22398. PubMed DOI

Duarte WR, Shibata T, Takenaga K, et al. S100A4: a novel negative regulator of mineralization and osteoblast differentiation. J Bone Miner Res. 2003;18:493–501. doi: 10.1359/jbmr.2003.18.3.493. PubMed DOI

Sack U, Walther W, Scudiero D, et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell. 2011;22:3344–3354. doi: 10.1091/mbc.e10-09-0739. PubMed DOI PMC

Kato C, Kojima T, Komaki M, et al. S100A4 inhibition by RNAi up-regulates osteoblast related genes in periodontal ligament cells. Biochem Biophys Res Commun. 2004;326:147–153. doi: 10.1016/j.bbrc.2004.11.010. PubMed DOI

Erlandsson MC, Svensson MD, Jonsson IM, et al. Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function. Biochim Biophys Acta - Mol Cell Res. 1833;2013:2653–2663. PubMed

Erlandsson MC, Bian L, Jonsson I-M, et al. Metastasin S100A4 is a mediator of sex hormone-dependent formation of the cortical bone. Mol Endocrinol. 2013;27:1311–1321. doi: 10.1210/me.2012-1398. PubMed DOI PMC

Liu F, Kohlmeier S, Wang CY. Wnt signaling and skeletal development. Cell Signal. 2008;20:999–1009. doi: 10.1016/j.cellsig.2007.11.011. PubMed DOI PMC

Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology. 2006;131:1486–1500. doi: 10.1053/j.gastro.2006.08.041. PubMed DOI

Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:572–574. doi: 10.1136/annrheumdis-2011-200216. PubMed DOI

Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783. doi: 10.1136/ard.2009.108233. PubMed DOI

Hulejová H, Kropáčková T, Bubová K, Kryštůfková O, Filková M, Mann H, Forejtová Š, Tomčík M, Vencovský J, Pavelka K, Šenolt L. Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatol Int. 2019;39:1037–1043. doi: 10.1007/s00296-019-04301-z. PubMed DOI

Prajzlerová K, Grobelná K, Hušáková M, Forejtová Š, Jüngel A, Gay S, Vencovský J, Pavelka K, Šenolt L, Filková M. Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS One. 2017;12:e0185323. doi: 10.1371/journal.pone.0185323. PubMed DOI PMC

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286–2291. PubMed

Dawes PT. Stoke Ankylosing spondylitis spine score. J Rheumatol. 1999;26:993–996. PubMed

Zibert JR, Skov L, Thyssen JP, et al. Significance of the S100A4 protein in psoriasis. J Invest Dermatol. 2010;130:150–160. doi: 10.1038/jid.2009.206. PubMed DOI

Andrés Cerezo L, Remáková M, Tomčik M, et al. The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatol (United Kingdom) 2014;53:1520–1526. PubMed

Oslejsková L, Grigorian M, Hulejová H, et al. Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1590–1594. doi: 10.1093/rheumatology/kep316. PubMed DOI

Senolt L, Cerezo LA, Sumova B, et al. High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. Biomarkers. 2015;20:47–51. doi: 10.3109/1354750X.2014.989544. PubMed DOI

Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases. Ann Rheum Dis. 2006;65:1645–1648. doi: 10.1136/ard.2005.047704. PubMed DOI PMC

Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J. Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. Rheumatol Int. 2019;39:469–478. doi: 10.1007/s00296-018-4190-2. PubMed DOI

Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73:437–445. doi: 10.1136/annrheumdis-2013-203643. PubMed DOI

Klingelhöfer J, Ambartsumian NS, Lukanidin EM. Expression of the metastasis-associated mts1 gene during mouse development. Dev Dyn. 1997;210:87–95. doi: 10.1002/(SICI)1097-0177(199710)210:2<87::AID-AJA2>3.0.CO;2-5. PubMed DOI

Diarra Danielle, Stolina Marina, Polzer Karin, Zwerina Jochen, Ominsky Michael S, Dwyer Denise, Korb Adelheid, Smolen Josef, Hoffmann Markus, Scheinecker Clemens, van der Heide Desiree, Landewe Robert, Lacey Dave, Richards William G, Schett Georg. Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine. 2007;13(2):156–163. doi: 10.1038/nm1538. PubMed DOI

Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69:592–597. doi: 10.1136/ard.2008.102046. PubMed DOI